Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells

被引:32
作者
Benedetti, L
Levin, AA
Scicchitano, BM
Grignani, F
Allenby, G
Diverio, D
LoCoco, F
Avvisati, G
Ruthardt, M
Adamo, S
Pelicci, PG
Nervi, C
机构
[1] UNIV ROMA LA SAPIENZA,DEPT HISTOL & MED EMBRYOL,I-00161 ROME,ITALY
[2] UNIV ROMA LA SAPIENZA,DEPT CELLULAR BIOTECHNOL & HEMATOL,I-00161 ROME,ITALY
[3] HOFFMANN LA ROCHE INC,DEPT TOXICOL & PATHOL,NUTLEY,NJ 07110
[4] UNIV PERUGIA,DEPT MED,I-06100 PERUGIA,ITALY
[5] EUROPEAN INST ONCOL,DEPT EXPT ONCOL,MILAN,ITALY
关键词
D O I
10.1182/blood.V90.3.1175.1175_1175_1185
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The bcr1- and bcr3- promyelocytic leukemia/retinoic acid receptor alpha (PML/RAR alpha) are the two major fusion proteins expressed in acute promyelocytic leukemia (APL) patients. These proteins, which are present in different lengths of PML (amino acids 1-552 and 1-394, respectively), contain most of the functional domains of PML and RAR alpha, bind all-trans-retinoic acid (t-RA), and act as t-RA-dependent transcription factors, T-RA is an effective inducer of clinical remission only in patients carrying the t(15;17) and expressing the PML/RAR alpha products. However, in APL patients achieving complete remission with t-RA therapy the bcr3-PML/RAR alpha product has been found associated with a poorer prognosis than bcr1-PML/RAR alpha. In the present study we have investigated the structural and functional properties of the bcr3-PML/RAR alpha in comparison to the previously characterized bcr1-PML/RAR alpha. In particular, we have measured the binding properties of the two endogenous ligands t-RA and 9-cis-RA to both of these isoforms. T-RA binding analysis of nuclear and cytosolic extracts prepared from bcr3-PML/RAR alpha APL patients and from bcr3-PML/RAR alpha COS-1 transfected cells indicates that this protein is present only as high-molecular-weight nuclear complexes. Using saturation binding assays and Scatchard analyses we found that t-RA binds with slightly less affinity to the bcr3-PML/RAR alpha receptor than to bcr1-PML/RAR alpha or RAR alpha (Kd = 0.4 nmol/L, 0.13 nmol/L or 0.09 nmol/L, respectively). Moreover, two different high-affinity 9-cis-RA binding sites (Kd = 0.45 and 0.075 nmol/L) were detectable in the bcr3-PML/RAR alpha product but not in the bcr1-PML/RAR alpha product (Kd = 0.77 nmol/L). By competition binding experiments we showed that 9-cis-RA binds with higher specificity to the bcr3-PML/RAR alpha isoform than to the bcr1-PML/RAR alpha or RAR alpha. Consistent with these data, the binding of 9-cis-RA to the bcr3-PML/RAR alpha product resulted in increased transcriptional activation of the RA-responsive element (RARE) TRE, but not of the beta RARE, in transiently transfected COS-1 cells. These results provide evidence indicating that preferential retinoid binding to the different PML/RAR alpha products can be measured. (C) 1997 by The American Society of Hematology.
引用
收藏
页码:1175 / 1185
页数:11
相关论文
共 55 条
  • [1] ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625
  • [2] RETINOIC ACID RECEPTORS AND RETINOID X-RECEPTORS - INTERACTIONS WITH ENDOGENOUS RETINOIC ACIDS
    ALLENBY, G
    BOCQUEL, MT
    SAUNDERS, M
    KAZMER, S
    SPECK, J
    ROSENBERGER, M
    LOVEY, A
    KASTNER, P
    GRIPPO, JF
    CHAMBON, P
    LEVIN, AA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (01) : 30 - 34
  • [3] AIDA (all-trans retinoic acid plus idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Pilot study
    Avvisati, G
    LoCoco, F
    Diverio, D
    Falda, M
    Ferrara, F
    Lazzarino, M
    Russo, D
    Petti, MC
    Mandelli, F
    [J]. BLOOD, 1996, 88 (04) : 1390 - 1398
  • [4] Benedetti L, 1996, BLOOD, V87, P1939
  • [5] PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) : 620 - 625
  • [6] BIONDI A, 1991, BLOOD, V77, P1418
  • [7] BLOMHOFF R, 1994, VITAMIN A HLTH DIS
  • [8] IDENTIFICATION OF A 2ND HUMAN RETINOIC ACID RECEPTOR
    BRAND, N
    PETKOVICH, M
    KRUST, A
    CHAMBON, P
    DETHE, H
    MARCHIO, A
    TIOLLAIS, P
    DEJEAN, A
    [J]. NATURE, 1988, 332 (6167) : 850 - 853
  • [9] PLZF-RAR-ALPHA FUSION PROTEINS GENERATED FROM THE VARIANT T(11-17)(Q23-Q21) TRANSLOCATION IN ACUTE PROMYELOCYTIC LEUKEMIA INHIBIT LIGAND-DEPENDENT TRANSACTIVATION OF WILD-TYPE RETINOIC ACID RECEPTORS
    CHEN, Z
    GUIDEZ, F
    ROUSSELOT, P
    AGADIR, A
    CHEN, SJ
    WANG, ZY
    DEGOS, L
    ZELENT, A
    WAXMAN, S
    CHOMIENNE, C
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (03) : 1178 - 1182
  • [10] FUSION BETWEEN A NOVEL KRUPPEL-LIKE ZINC FINGER GENE AND THE RETINOIC ACID RECEPTOR-ALPHA LOCUS DUE TO A VARIANT T(11,17) TRANSLOCATION ASSOCIATED WITH ACUTE PROMYELOCYTIC LEUKEMIA
    CHEN, Z
    BRAND, NJ
    CHEN, A
    CHEN, SJ
    TONG, JH
    WANG, ZY
    WAXMAN, S
    ZELENT, A
    [J]. EMBO JOURNAL, 1993, 12 (03) : 1161 - 1167